BR112023016271A2 - Métodos para usar anticorpos que reconhecem tau - Google Patents

Métodos para usar anticorpos que reconhecem tau

Info

Publication number
BR112023016271A2
BR112023016271A2 BR112023016271A BR112023016271A BR112023016271A2 BR 112023016271 A2 BR112023016271 A2 BR 112023016271A2 BR 112023016271 A BR112023016271 A BR 112023016271A BR 112023016271 A BR112023016271 A BR 112023016271A BR 112023016271 A2 BR112023016271 A2 BR 112023016271A2
Authority
BR
Brazil
Prior art keywords
antibodies
methods
tau
recognize tau
recognize
Prior art date
Application number
BR112023016271A
Other languages
English (en)
Inventor
James Dolan Philip Iii
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of BR112023016271A2 publication Critical patent/BR112023016271A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos para usar anticorpos que reconhecem tau. a invenção fornece métodos para tratar taupatias, tal como doença de alzheimer, com anticorpos que se ligam à tau humana. os anticorpos inibem ou retardam as patologias associadas a tau e deterioração sintomática associada.
BR112023016271A 2021-02-14 2022-02-11 Métodos para usar anticorpos que reconhecem tau BR112023016271A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149359P 2021-02-14 2021-02-14
PCT/US2022/016105 WO2022174026A1 (en) 2021-02-14 2022-02-11 Methods of using antibodies recognizing tau

Publications (1)

Publication Number Publication Date
BR112023016271A2 true BR112023016271A2 (pt) 2023-11-14

Family

ID=82837931

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016271A BR112023016271A2 (pt) 2021-02-14 2022-02-11 Métodos para usar anticorpos que reconhecem tau

Country Status (13)

Country Link
US (2) US20220267426A1 (pt)
EP (1) EP4291234A1 (pt)
JP (1) JP2024506391A (pt)
KR (1) KR20230146056A (pt)
CN (1) CN117136073A (pt)
AU (1) AU2022219986A1 (pt)
BR (1) BR112023016271A2 (pt)
CA (1) CA3208191A1 (pt)
CL (1) CL2023002414A1 (pt)
IL (1) IL305161A (pt)
MX (1) MX2023009470A (pt)
TW (1) TW202246320A (pt)
WO (1) WO2022174026A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115657C2 (uk) * 2011-09-19 2017-12-11 Аксон Ньюросайєнс Сє Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
KR101582852B1 (ko) * 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
UA124148C2 (uk) * 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
BR112019022906A2 (pt) * 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
SG11202108414UA (en) * 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
EP3725370A1 (en) * 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
EP3963055A1 (en) * 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Vectorized antibodies (vab) and uses thereof

Also Published As

Publication number Publication date
IL305161A (en) 2023-10-01
US20220267426A1 (en) 2022-08-25
CL2023002414A1 (es) 2024-02-23
CA3208191A1 (en) 2022-08-18
MX2023009470A (es) 2023-09-21
JP2024506391A (ja) 2024-02-13
CN117136073A (zh) 2023-11-28
TW202246320A (zh) 2022-12-01
WO2022174026A1 (en) 2022-08-18
KR20230146056A (ko) 2023-10-18
AU2022219986A1 (en) 2023-08-31
US20240018226A1 (en) 2024-01-18
EP4291234A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
BR112021011431A2 (pt) Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
CL2018001971A1 (es) Ror1 composiciones de anticuerpos y métodos relacionados
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CO2017013356A2 (es) Anticuerpos de factor xi
CO2018014325A2 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
CO2017012974A2 (es) Anticuerpos de unión a tau
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
BR112019022906A2 (pt) Anticorpos que reconhecem tau
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
BR112019008417A2 (pt) compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y
BR112021016947A2 (pt) Anticorpos que reconhecem tau
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
BR112022003147A2 (pt) Novos anticorpos anti-cldn18.2
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
BR112018072394A2 (pt) anticorpos que reconhecem a tau
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
NI201900086A (es) Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo.
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
BR112017002703A2 (pt) anticorpos específicos de mmp9.
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos